Literature DB >> 18056464

Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.

Jens E Ruhe1, Sylvia Streit, Stefan Hart, Chee-Hong Wong, Katja Specht, Pjotr Knyazev, Tatjana Knyazeva, Liang Seah Tay, Hooi Linn Loo, Priscilla Foo, Winnie Wong, Sharon Pok, Shu Jing Lim, Huimin Ong, Ming Luo, Han Kiat Ho, Kaitian Peng, Tze Chuen Lee, Martin Bezler, Christian Mann, Silvia Gaertner, Heinz Hoefler, Stefano Iacobelli, Stephan Peter, Alice Tay, Sydney Brenner, Byrappa Venkatesh, Axel Ullrich.   

Abstract

Protein tyrosine kinases (PTKs) play a critical role in the manifestation of cancer cell properties, and respective signaling mechanisms have been studied extensively on immortalized tumor cells. To characterize and analyze commonly used cancer cell lines with regard to variations in the primary structure of all expressed PTKs, we conducted a cDNA-based sequence analysis of the entire tyrosine kinase transcriptome of 254 established tumor cell lines. The profiles of cell line intrinsic PTK transcript alterations and the evaluation of 155 identified polymorphisms and 234 somatic mutations are made available in a database designated "Tykiva" (tyrosine kinome variant). Tissue distribution analysis and/or the localization within defined protein domains indicate functional relevance of several genetic alterations. The cysteine replacement of the highly conserved Y367 residue in fibroblast growth factor receptor 4 or the Q26X nonsense mutation in the tumor-suppressor kinase CSK are examples, and may contribute to cell line-specific signaling characteristics and tumor progression. Moreover, known variants, such as epidermal growth factor receptor G719S, that were shown to mediate anticancer drug sensitivity could be detected in other than the previously reported tumor types. Our data therefore provide extensive system information for the design and interpretation of cell line-based cancer research, and may stimulate further investigations into broader clinical applications of current cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056464     DOI: 10.1158/0008-5472.CAN-07-2703

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 2.  Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis.

Authors:  Ombretta Salvucci; Giovanna Tosato
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

3.  Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells.

Authors:  Boon Tin Chua; Shu Jing Lim; Su Chin Tham; Wei Jie Poh; Axel Ullrich
Journal:  Mol Oncol       Date:  2010-03-19       Impact factor: 6.603

Review 4.  Roles of FGFR in oral carcinogenesis.

Authors:  Xiaoyan Xie; Zhiyong Wang; Fangman Chen; Yao Yuan; Jiayi Wang; Rui Liu; Qianming Chen
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

5.  Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.

Authors:  Erika M Lisabeth; Carlos Fernandez; Elena B Pasquale
Journal:  Biochemistry       Date:  2012-02-08       Impact factor: 3.162

Review 6.  Eph-dependent cell-cell adhesion and segregation in development and cancer.

Authors:  Eva Nievergall; Martin Lackmann; Peter W Janes
Journal:  Cell Mol Life Sci       Date:  2011-12-28       Impact factor: 9.261

Review 7.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

8.  Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer.

Authors:  Lee Cheng Phua; Hui Wen Ng; Angie Hui Ling Yeo; Elya Chen; Michelle Shu Mei Lo; Peh Yean Cheah; Eric Chun Yong Chan; Poh Koon Koh; Han Kiat Ho
Journal:  Oncol Lett       Date:  2015-08-03       Impact factor: 2.967

Review 9.  ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  Cancer Lett       Date:  2013-04-15       Impact factor: 8.679

10.  Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.

Authors:  Audrey Sirvent; Christine Benistant; Serge Roche
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.